Literature DB >> 15206014

Addition of a second opioid may improve opioid response in cancer pain: preliminary data.

Sebastiano Mercadante1, Patrizia Villari, Patrizia Ferrera, Alessandra Casuccio.   

Abstract

Recent experimental data suggest a possible use of an opioid combination to improve analgesia. In cancer patients, a rapid opioid escalation due to either worsening of the pain condition or the development of tolerance is a critical phase, as this condition is associated with a negative prognosis. The aim of this study was to assess the effects of adding a second opioid at low doses in patients with a poor analgesic benefit after dose escalation. Fourteen patients receiving strong opioids who had increased their dosage more than 100% in the last week unsuccessfully were randomly chosen to add a second opioid to the first using an initial equivalent dosage of 20% of the previous therapy. The dose of the second opioid was then changed according to the clinical situation to obtain an acceptable pain control with minimal adverse effects. Pain and symptoms associated with opioid therapy were assessed, and an opioid escalation index (OEI) was calculated at weekly intervals. OEI significantly decreased after adding the second opioid, and this trend was also maintained for the following weeks. Similarly, pain intensity was significantly improved and maintained at acceptable levels for the following weeks. The second opioid did not induce significant opioid-related adverse effects. The opioid combination was able to break opioid escalation in patients with pain syndromes with a poor response to the previous opioid. It allowed for a regaining of analgesia, regardless of the opioid combination used. These preliminary observations should be confirmed in further studies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15206014     DOI: 10.1007/s00520-004-0650-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  18 in total

Review 1.  Opioid use in cancer pain. Is a more liberal approach enhancing toxicity?

Authors:  P J Daeninck; E Bruera
Journal:  Acta Anaesthesiol Scand       Date:  1999-10       Impact factor: 2.105

Review 2.  Accuracy in equianalgesic dosing. conversion dilemmas.

Authors:  R Anderson; J H Saiers; S Abram; C Schlicht
Journal:  J Pain Symptom Manage       Date:  2001-05       Impact factor: 3.612

Review 3.  Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy.

Authors:  Jianren Mao
Journal:  Pain       Date:  2002-12       Impact factor: 6.961

4.  Investigation of an opioid response categorization in advanced cancer patients.

Authors:  S Mercadante; F Fulfaro; A Casuccio; L Barresi
Journal:  J Pain Symptom Manage       Date:  1999-11       Impact factor: 3.612

Review 5.  Tolerance to opioid analgesics: clinical aspects.

Authors:  R K Portenoy
Journal:  Cancer Surv       Date:  1994

6.  Chronic morphine treatment inhibits opioid receptor desensitization and internalization.

Authors:  Daniela A Eisinger; Hermann Ammer; Rüdiger Schulz
Journal:  J Neurosci       Date:  2002-12-01       Impact factor: 6.167

7.  Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization.

Authors:  Li He; Jamie Fong; Mark von Zastrow; Jennifer L Whistler
Journal:  Cell       Date:  2002-01-25       Impact factor: 41.582

8.  Disappearance of morphine-induced hyperalgesia after discontinuing or substituting morphine with other opioid agonists.

Authors:  Per Sjøgren; Niels-Henrik Jensen; Troels Staehelin Jensen
Journal:  Pain       Date:  1994-11       Impact factor: 6.961

9.  Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain.

Authors:  Barbara Donner; Michael Zenz; Michael Tryba; Michael Strumpf
Journal:  Pain       Date:  1996-03       Impact factor: 6.961

10.  Opioid rotation for toxicity reduction in terminal cancer patients.

Authors:  N D de Stoutz; E Bruera; M Suarez-Almazor
Journal:  J Pain Symptom Manage       Date:  1995-07       Impact factor: 3.612

View more
  15 in total

1.  Gaps and junctions between clinical experience and theoretical framework in the use of opioids.

Authors:  Marianne Kloke
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

Review 2.  Look before leaping: combined opioids may not be the rave.

Authors:  Mellar P Davis; Susan B LeGrand; Ruth Lagman
Journal:  Support Care Cancer       Date:  2005-07-06       Impact factor: 3.603

3.  Promoting science in a pragmatic world: not (yet) time for partial opioid rotation.

Authors:  Florian Strasser
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

Review 4.  Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction.

Authors:  M J Christie
Journal:  Br J Pharmacol       Date:  2008-04-14       Impact factor: 8.739

5.  Effect of dose escalation with single opioid, fentanyl matrix in patients not controlling cancer pain: a multicenter, prospective, observational study in Korea.

Authors:  Sung Ae Koh; Kyung Hee Lee; Mi Jung Kim; Kyu Taek Lee; Seung Woo Park; Seung Hyun Nam; Hun Mo Ryoo
Journal:  Cancer Res Treat       Date:  2013-12-31       Impact factor: 4.679

Review 6.  Preclinical pharmacology and opioid combinations.

Authors:  Gavril W Pasternak
Journal:  Pain Med       Date:  2012-03       Impact factor: 3.750

7.  Lack of Antinociceptive Cross-Tolerance With Co-Administration of Morphine and Fentanyl Into the Periaqueductal Gray of Male Sprague-Dawley Rats.

Authors:  Erin N Bobeck; Shauna M Schoo; Susan L Ingram; Michael M Morgan
Journal:  J Pain       Date:  2019-03-07       Impact factor: 5.820

8.  High-dose fentanyl patch for cancer pain of a patient with cholangiocarcinoma.

Authors:  Jung Han Kim; Mi Kim; Chong Won Sung; Hyeoung Su Kim; Hyun Joo Jang; Young Chul Shin; Joo Young Jung
Journal:  Korean J Intern Med       Date:  2010-08-31       Impact factor: 2.884

Review 9.  Management of breakthrough pain in patients with cancer.

Authors:  Leeroy William; Rod Macleod
Journal:  Drugs       Date:  2008       Impact factor: 9.546

10.  The role of methadone in opioid rotation-a Polish experience.

Authors:  Wojciech Leppert
Journal:  Support Care Cancer       Date:  2008-11-29       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.